PKS Advisory Services’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-9,581
Closed -$239K 256
2025
Q4
$239K Sell
9,581
-2,040
-18% -$51.4K 0.05% 221
2025
Q3
$296K Buy
11,621
+1,173
+11% +$29K 0.06% 193
2025
Q2
$253K Sell
10,448
-2,596
-20% -$60.5K 0.06% 225
2025
Q1
$327K Buy
13,044
+849
+7% +$22.2K 0.09% 169
2024
Q4
$324K Buy
+12,195
New +$331K 0.08% 180

Other funds holding PFE

PKS Advisory Services's PFE Position: Q1 2026 in Review

PKS Advisory Services sold out of Pfizer (PFE) in Q1 2026, closing a stake of 9,581 shares — an estimated $239K sold.

PKS Advisory Services first reported a position in PFE in Q4 2024 and held it in 5 quarters. The position peaked at $327K in Q1 2025. 2,934 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • PKS Advisory Services reported no remaining Pfizer position as of Q1 2026 after selling out during the quarter.
  • PKS Advisory Services sold 9,581 Pfizer shares in Q1 2026, an estimated $239K.
  • PKS Advisory Services first reported a position in Pfizer in Q4 2024 and held it in 5 quarters.
  • PKS Advisory Services's Pfizer position peaked at $327K in Q1 2025.
  • 2,934 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on PKS Advisory Services's 13F filing for Q1 2026, filed 13 May 2026.